Table 3.
Most common drug-related adverse events in the DESTINY-Breast03 trial by overall population and Asian subgroup [50]
| Event, n (%) | Overall | Asian patients | ||||||
|---|---|---|---|---|---|---|---|---|
| T-DXd (n = 257) | T-DM1 (n = 261) | T-DXd (n = 147) | T-DM1 (n = 159) | |||||
| Any grade | Grade ≥ 3 | Any grade | Grade ≥ 3 | Any grade | Grade ≥ 3 | Any grade | Grade ≥ 3 | |
| Blood and lymphatic system disorders | ||||||||
| Neutropeniaa | 110 (42.8) | 49 (19.1) | 29 (11.1) | 8 (3.1) | 70 (47.6) | 36 (24.5) | 23 (14.5) | 8 (5.0) |
| Anaemiab | 78 (30.4) | 15 (5.8) | 37 (14.2) | 11 (4.2) | 47 (32.0) | 12 (8.2) | 22 (13.8) | 6 (3.8) |
| Thrombocytopeniac | 64 (24.9) | 18 (7.0) | 135 (51.7) | 65 (24.9) | 49 (33.3) | 17 (11.6) | 103 (64.8) | 55 (34.6) |
| Gastrointestinal disorders | ||||||||
| Nausea | 187 (72.8) | 17 (6.6) | 72 (27.6) | 1 (0.4) | 96 (65.3) | 6 (4.1) | 34 (21.4) | 1 (0.6) |
| Vomiting | 113 (44.0) | 4 (1.6) | 15 (5.7) | 1 (0.4) | 63 (42.9) | 2 (1.4) | 7 (4.4) | 1 (0.6) |
| General disorders | ||||||||
| Fatigued | 115 (44.7) | 13 (5.1) | 77 (29.5) | 2 (0.8) | 63 (42.9) | 8 (5.4) | 38 (23.9) | 1 (0.6) |
| Skin and subcutaneous tissue disorders | ||||||||
| Alopecia | 93 (36.2) | 1 (0.4) | 6 (2.3) | 0 | 56 (38.1) | 0 | 4 (2.5) | 0 |
ILD interstitial lung disease, T-DM1 trastuzumab emtansine, T-DXd trastuzumab deruxtecan
aThis category includes the preferred terms neutrophil count decreased and neutropenia [50]
bThis category includes the preferred terms haemoglobin decreased, red blood cell count decreased, anaemia and haematocrit decreased [50]
cThis category includes the preferred terms platelet count decreased and thrombocytopenia [50]
dThis category includes the preferred terms fatigue, asthenia and malaise [50]